U.S. Markets closed

The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise

Zacks Equity Research
MEET vs. WDAY: Which Stock Is the Better Value Option?

For Immediate Release

Chicago, IL –June 29, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson JNJ, Biogen BIIB, General Motors GM, Valero Energy VLO and Ameriprise Financial AMP.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for Johnson & Johnson, Biogen and General Motors

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Biogen and General Motors. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Johnson & Johnson’s shares have lost -5.1% in the last three months, underperforming the -2.4% decline of the Zacks Large Cap Pharmaceuticals industry. J&J’s sales growth has accelerated since the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices & Consumer segments.

Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, the Zacks analyst thinks new products in all segments, successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from recent acquisitions will continue to drive top-line growth. J&J also enjoys a robust multi-year pipeline of new drugs and line extensions.

Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. Headwinds like generics, pricing pressure, sluggish growth in the Medical Device segment and soft global market conditions remain.

Shares of Biogen have underperformed the Zacks Biomedical and Genetics industry year to date (-9.7% vs. -9.5%). Biogen has a strong position in the MS market with a wide range of products - Avonex, Tysabri, Tecfidera & Plegridy. The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke, among others.

Meanwhile, its newest drug, Spinraza, has multi-billion dollar potential. Biogen’s efforts to regularly in-license assets to build its pipeline are also encouraging. It has many assets in its pipeline, which have transformative potential. Multiple data read-outs are expected this year.

However, the launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the United States, mainly on Tysabri. Also, Spinraza’s moderating trends in the United States is a concern. Also, recently, Biogen announced the decision to withdraw Zinbryta from the markets due to growing safety concerns.

Buy-rankedGeneral Motors’ shares have outperformed the Zacks Domestic Automotive industry over the last three months, increasing +11.1% vs. +10.9%. General Motors expects weak used car pricing, a challenging pricing environment in the U.S. and China as well as more pressure on commodity costs.

Also, the company is facing a high inventory level of passenger cars. It is working toward bringing the inventory down by cutting production. Moreover, the company has been forced to scale down or shut its manufacturing operations in some regions due to production constraints such as high costs and unfavorable currency translation effects.

However, the company’s capital allocation strategy, initiatives to make its vehicles more advanced, safer and fuel efficient and focus on technology development are likely to benefit it.

Other noteworthy reports we are featuring today include Valero Energy and Ameriprise Financial.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
General Motors Company (GM) : Free Stock Analysis Report
Ameriprise Financial, Inc. (AMP) : Free Stock Analysis Report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Valero Energy Corporation (VLO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research